SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

SANTA CRUZ BIOTECHNOLOGY, INC.

SATB2 (SATBA4B10): sc-81376

BACKGROUND

SATB2 (special AT-rich sequence-binding protein 2) is a nuclear matrix protein that influences craniofacial formation mechanisms, such as jaw and palate development, and is part of a transcriptional network regulating skeletal development and osteoblast differentiation. Highly expressed in adult and fetal brain, SATB2 contains two CUT DNA-binding domains and one homeobox domain and is closely related to SATB1, a transcriptional repressor. SATB2 is thought to bind to matrix attachment regions (MARs) and regulate MAR-dependent transcription of various genes, including HoxA2 and ATF-4 (CREB-2), involved in skeletal development. Functioning as both a transcriptional activator and repressor, SATB2 can also act as a protein scaffold that can enhance the activity of other DNA-binding proteins. Defects in the gene encoding SATB2 are the cause of cleft palate manifested in conjunction with severe mental retardation.

CHROMOSOMAL LOCATION

Genetic locus: SATB2 (human) mapping to 2q33.1; Satb2 (mouse) mapping to 1 C1.3.

SOURCE

SATB2 (SATBA4B10) is a mouse monoclonal antibody raised against a recombinant protein corresponding to the C-terminal region of SATB2 of human origin.

PRODUCT

Each vial contains 100 µg IgG_1 kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 1.0% stabilizer protein.

APPLICATIONS

SATB2 (SATBA4B10) is recommended for detection of SATB2 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)] and immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

Suitable for use as control antibody for SATB2 siRNA (h): sc-76456, SATB2 siRNA (m): sc-76457, SATB2 siRNA (r): sc-61891, SATB2 shRNA Plasmid (h): sc-76456-SH, SATB2 shRNA Plasmid (m): sc-76457-SH, SATB2 shRNA Plasmid (r): sc-61891-SH, SATB2 shRNA (h) Lentiviral Particles: sc-76456-V, SATB2 shRNA (m) Lentiviral Particles: sc-76457-V and SATB2 shRNA (r) Lentiviral Particles: sc-61891-V.

Molecular Weight of SATB2: 105 kDa.

Positive Controls: KNRK nuclear extract: sc-2141, NIH/3T3 whole cell lysate: sc-2210 or C6 whole cell lysate: sc-364373.

STORAGE

For immediate and continuous use, store at 4° C for up to one month. For sporadic use, freeze in working aliquots in order to avoid repeated freeze/thaw cycles. If turbidity is evident upon prolonged storage, clarify solution by centrifugation.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA



SATB2 (SATBA4B10): sc-81376. Western blot analysis of SATB2 expression in SH-SY5Y nuclear extract (**A**), NIH/3T3 (**B**) and C6 (**C**) whole cell lysates and mouse brain (**D**) and rat brain (**E**) tissue extracts.



SATB2 (SATBA4B10): sc-81376. Western blot analysis of SATB2 expression in KNRK (**A**), HT-1080 (**B**) and SH-SY5Y (**C**) nuclear extracts.

SELECT PRODUCT CITATIONS

1. Magnusson, K., et al. 2011. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am. J. Surg. Pathol. 35: 937-948.
2. Kobayashi, M., et al. 2014. Reappraisal of the immunophenotype of pancreatic intraductal papillary mucinous neoplasms (IPMNs)—gastric pyloric and small intestinal immunophenotype expression in gastric and intestinal type IPMNs—. Acta Histochem. Cytochem. 47: 45-57.
3. Liu, R., et al. 2015. Fstl1 is involved in the regulation of radial glial scaffold development. Mol. Brain 8: 53.
4. Gertz, C.C. and Kriegstein, A.R. 2015. Neuronal migration dynamics in the developing ferret cortex. J. Neurosci. 35: 14307-14315.
5. Righi, A., et al. 2015. Sclerosing epithelioid fibrosarcoma of the thigh: report of two cases with synchronous bone metastases. Virchows Arch. 467: 339-344.
6. Righi, A., et al. 2015. Small cell osteosarcoma: clinicopathologic, immunohistochemical, and molecular analysis of 36 cases. Am. J. Surg. Pathol. 39: 691-699.
7. Múnera, J.O., et al. 2017. Differentiation of human pluripotent stem cells into colonic organoids via transient activation of BMP signaling. Cell Stem Cell 21: 51-64.
8. Ludwig, K., et al. 2017. BCOR-CCNB3 undifferentiated sarcoma-does immunohistochemistry help in the identification? Pediatr. Dev. Pathol. 20: 321-329.
9. Chen, P., et al. 2017. MicroRNA-449a modulates medullary thymic epithelial cell differentiation. Sci. Rep. 7: 15915.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.